These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION. Lotfy A; Solaiman KAM; Abdelrahman A; Samir A Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552 [TBL] [Abstract][Full Text] [Related]
8. Intravitreal ziv-aflibercept for the treatment of choroidal neovascularisation associated with conditions other than age-related macular degeneration. Braimah IZ; Stewart M; Videkar C; Dedhia CJ; Chhablani J; Br J Ophthalmol; 2017 Sep; 101(9):1201-1205. PubMed ID: 28119292 [TBL] [Abstract][Full Text] [Related]
14. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study. Clark WL; Boyer DS; Heier JS; Brown DM; Haller JA; Vitti R; Kazmi H; Berliner AJ; Erickson K; Chu KW; Soo Y; Cheng Y; Campochiaro PA Ophthalmology; 2016 Feb; 123(2):330-336. PubMed ID: 26522708 [TBL] [Abstract][Full Text] [Related]
15. [New perspectives in the approach to diabetic macular edema. Aflibercept therapy]. Ruiz-Moreno JM Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():24-8. PubMed ID: 25925048 [TBL] [Abstract][Full Text] [Related]
16. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Brown DM; Heier JS; Clark WL; Boyer DS; Vitti R; Berliner AJ; Zeitz O; Sandbrink R; Zhu X; Haller JA Am J Ophthalmol; 2013 Mar; 155(3):429-437.e7. PubMed ID: 23218699 [TBL] [Abstract][Full Text] [Related]
17. Intravitreal aflibercept for diabetic macular edema. Korobelnik JF; Do DV; Schmidt-Erfurth U; Boyer DS; Holz FG; Heier JS; Midena E; Kaiser PK; Terasaki H; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Brown DM Ophthalmology; 2014 Nov; 121(11):2247-54. PubMed ID: 25012934 [TBL] [Abstract][Full Text] [Related]
18. SHORT-TERM SAFETY PROFILE OF INTRAVITREAL ZIV-AFLIBERCEPT. Chhablani J; Narayanan R; Mathai A; Yogi R; Stewart M Retina; 2016 Jun; 36(6):1126-31. PubMed ID: 26655620 [TBL] [Abstract][Full Text] [Related]
19. One-Year Results of a Trial Comparing 2 Doses of Intravitreal Ziv-aflibercept versus Bevacizumab for Treatment of Diabetic Macular Edema. Jabbarpoor Bonyadi MH; Baghi A; Ramezani A; Yaseri M; Soheilian M Ophthalmol Retina; 2018 May; 2(5):428-440. PubMed ID: 31047323 [TBL] [Abstract][Full Text] [Related]
20. Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept. Gonzalez VH; Boyer DS; Schmidt-Erfurth U; Heier JS; Gordon C; Benz MS; Marcus DM; Sabates NR; Vitti R; Kazmi H; Berliner AJ; Soo Y; Zhu X; Moini H; Zeitz O; Sandbrink R; Do DV Retina; 2015 Apr; 35(4):687-94. PubMed ID: 25621943 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]